RHEUMATOLOGY

Filed Under News 

Association of Triple Therapy With Improvement in Cholesterol Profiles

 

According to an article published online in Arthritis and Rheumatology (24 February 2016), a study was performed to evaluate long-term changes in cholesterol levels in patients with early rheumatoid arthritis (RA) who were randomized to begin treatment with methotrexate (MTX) monotherapy, MTX plus etanercept, or triple therapy (MTX plus sulfasalazine plus hydroxychloroquine) in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial.

 

For the study, levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol were analyzed in 416 patients participating in the TEAR trial, during 102 weeks of followup. Associations of cholesterol changes with disease activity and drug treatment were evaluated using repeated-measures analysis with mixed-effect linear models to model within-subject covariance over time.

 

Results showed, after models controlling for traditional cardiovascular (CV) risk factors, TEAR treatment, and baseline prednisone and statin use demonstrated significant inverse associations of RA disease activity with changes in cholesterol over time. Decreases in the 28-joint Disease Activity Score, the C-reactive protein level, or the erythrocyte sedimentation rate (ESR) were associated with increases in levels of HDL cholesterol, LDL cholesterol, and total cholesterol in all treatment groups (P <0.001-0.035). Triple therapy was strongly associated with higher levels of HDL cholesterol, lower levels of LDL cholesterol, and higher ratios of total cholesterol:HDL cholesterol (P <0.001 for all) compared to MTX monotherapy or MTX plus etanercept therapy over the 2-year follow-up.

 

The authors concluded that decreases in RA disease activity over long-term follow-up were associated with increases in cholesterol levels in patients with early RA treated with either biologic or nonbiologic therapies, and that the use of triple therapy during 2 years of follow-up was associated with higher HDL cholesterol levels, lower LDL cholesterol levels, and lower total cholesterol:HDL cholesterol ratios compared to those observed in patients who received MTX monotherapy or MTX plus etanercept combination therapy. The authors stated that additional studies are needed to assess the effects of these cholesterol changes on CV events in patients with RA.

 

Comments

Leave a Reply

You must be logged in to post a comment.